PRME News & Events

Prime Medicine announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to PM359, an investigational autologous Prime Edited hematopoietic stem cell therapy for the treatment of p47phox-deficient chronic granulomatous disease.

Prime Medicine announced that the New Zealand Medicines and Medical Devices Safety Authority has cleared the Company's Clinical Trial Application for PM577a, an investigational Prime Editor for Wilson Disease. The clearance represents the first clinical authorization for an in vivo Prime Editing therapy from Prime Medicine and enables the initiation of the Company's global Phase 1/2 study.